China’s Public Payer Proposes Relaxing Novel Chemical Drug Pricing
Only drugs awarded high points under a government-designated scoring method will benefit most from a new pricing scheme in China. The criteria include the products’ innovativeness in terms of pharmaceutical sciences, the clinical value for patients and clinical evidence from clinical studies.
You may also be interested in...
Brian Yang, Dexter Yan and guest speaker Kevin Grogan from the UK discuss Shanghai's latest policy to spur biopharma investment, the US House's recent draft bill to restrict bio service providers from China, and multinationals' strategies in China and views on Chinese innovation.
Beijing-based Innolife claims that its drug candidate INL1 can deliver trace elements directly to damaged cardiac tissue. The targeted approach is aimed at activating HIF-1, a protein crucial for growth and oxygen supply and which can promote tissue repair.
Jiangsu Vcare Pharmatech, Neurodawn Pharmaceutical and Shanghai Synvida Biotechnology stand out with funding rounds that each grossed roughly CNY200m ($28m) and above.